Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161385 | 0.83 | HDAC1 (0.56) | SIRT2HDAC1HDAC2HDAC8LMNA | |
| SCHEMBL563342 | 0.83 | ALDH1A1 (0.73) | HDAC1HDAC2HDAC8LMNAMAPT | |
| SCHEMBL17978611 | 0.82 | SIRT2 (0.76) | SIRT2HDAC1HDAC2HDAC8LMNA | |
| SCHEMBL5717586 | 0.81 | TSHR (0.67) | SIRT2HDAC1HDAC2HDAC8LMNA | |
| SCHEMBL160793 | 0.80 | HDAC2 (0.57) | SIRT2HDAC1HDAC2HDAC8LMNA | |
| SCHEMBL5717819 | 0.80 | SIRT2 (0.65) | SIRT2HDAC1HDAC2HDAC8LMNA | |
| SCHEMBL162484 | 0.78 | HDAC8 (0.56) | HDAC1HDAC8LMNAMAPTALDH1A1 | |
| SCHEMBL5469179 | 0.78 | MAPT (0.70) | SIRT2HDAC1HDAC2HDAC8LMNA | |
| SCHEMBL6333033 | 0.77 | LMNA (0.61) | HDAC1LMNAMAPTALDH1A1NPC1 | |
| SCHEMBL5330749 | 0.76 | SIRT2 (0.67) | SIRT2HDAC1HDAC2HDAC8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | SIRT2 472/4885HDAC1 949/4885HDAC2 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.